Mark H.H. Kramer

9.0k citations

154 papers · 5.8k indexed · 3 hit papers · h-index 42

Impact in

Internal Medicine top 0.5%
- Venous Thromboembolism Diagnosis and Management
Endocrinology, Diabetes and Metabolism top 0.5%
- Diabetes Treatment and Management
- Diabetes Management and Research

Papers in ⓘ

Family Practice 8
Internal Medicine 13
- Venous Thromboembolism Diagnosis and Management 13

Co-authors: Daniël H. van Raalte (42 shared papers)Mark M. Smits (32 shared papers)Marcel H.A. Muskiet (34 shared papers)Lennart Tonneijck (29 shared papers)Michaëla Diamant (21 shared papers)Prabath W.B. Nanayakkara (31 shared papers)Jaap A. Joles (13 shared papers)Max Nieuwdorp (21 shared papers)
Journals: Diabetes Obesity and Metabolism (12 papers)European Journal of Internal Medicine (8 papers)European Journal of Endocrinology (4 papers)Diabetes Care (4 papers)Journal of Antimicrobial Chemotherapy (4 papers)
Partner nations: Netherlands United States Vietnam

In The Last Decade

Mark H.H. Kramer

151 papers receiving 5.7k citations

Hit Papers

align trajectories log scale

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial 2019 · 253 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Kidney International
2017 Nature Reviews Nephrology
2016 The Lancet Diabetes & Endocrinology

Peers

Countries citing papers authored by Mark H.H. Kramer

Since Specialization

Citations

This map shows the geographic impact of Mark H.H. Kramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark H.H. Kramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark H.H. Kramer more than expected).

Fields of papers citing papers by Mark H.H. Kramer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark H.H. Kramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark H.H. Kramer. The network helps show where Mark H.H. Kramer may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark H.H. Kramer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark H.H. Kramer Line = papers co-authored together Mark H.H. Kramer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 154 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes Nature Reviews Nephrology ·Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, Michaël J.B. van Baar, Mark H.H. Kramer, Ewout J. Hoorn, Jaap A. Joles, Daniël H. van Raalte Hit paper breakdown →	2017	294
2	Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial The Lancet Diabetes & Endocrinology ·C.A.J. van Beers, J. Hans DeVries, Susanne J. Kleijer, Mark M. Smits, Petronella Geelhoed-Duijvestijn, Mark H.H. Kramer, Michaëla Diamant, Frank J. Snoek, Erik H. Serné Hit paper breakdown →	2016	289
3	Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study British Journal of Haematology ·Michael Hedenus, Magnus Adriansson, Jesús F. San Miguel, Mark H.H. Kramer, Martin R. Schipperus, Eeva Juvonen, Kerry Taylor, Andrew Belch, Albert Altés, Giovanni Martinelli, David I. Watson, James Matcham, Gregory Rossi, Timothy J. Littlewood	2003	267
4	The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial Kidney International ·Erik J.M. van Bommel, Marcel H.A. Muskiet, Michaël J.B. van Baar, Lennart Tonneijck, Mark M. Smits, Anna L. Emanuel, Andrea Božović, A.H. Jan Danser, Frank Geurts, Ewout J. Hoorn, Daan J. Touw, Emil List Larsen, Henrik E. Poulsen, Mark H.H. Kramer, Max Nieuwdorp, Jaap A. Joles, Daniël H. van Raalte Hit paper breakdown →	2019	253
5	Effect of nutritional interventions on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo)radiotherapy: a systematic review Clinical Nutrition ·J.A.E. Langius, Myrna C. Zandbergen, Simone E. J. Eerenstein, Maurits W. van Tulder, C. René Leemans, Mark H.H. Kramer, Peter J.M. Weijs	2013	219
6	SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome Clinical Journal of the American Society of Nephrology ·Erik J.M. van Bommel, Marcel H.A. Muskiet, Lennart Tonneijck, Mark H.H. Kramer, Max Nieuwdorp, Daniël H. van Raalte	2017	172
7	Risk factors for post‐thrombotic syndrome in patients with a first deep venous thrombosis Journal of Thrombosis and Haemostasis ·Lidwine W. Tick, Mark H.H. Kramer, Frits R. Rosendaal, Wladimir Faber, Carine J.M. Doggen	2008	162
8	Prevalence and determinants for malnutrition in geriatric outpatients Clinical Nutrition ·M.A.E. de van der Schueren, Sabine Lonterman‐Monasch, Oscar J. de Vries, Sven A. Danner, Mark H.H. Kramer, Majon Muller	2013	144
9	Exploring the performance of the National Early Warning Score (NEWS) in a European emergency department Resuscitation ·Nadia Alam, I.L. Vegting, Edith N. G. Houben, B. van Berkel, Louella Vaughan, Mark H.H. Kramer, Prabath W.B. Nanayakkara	2015	129
10	Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial BMJ ·Jan Jelrik Oosterheert, Marc J. M. Bonten, M. M. E. Schneider, Erik Buskens, Jan‐Willem J. Lammers, Willem M N Hustinx, Mark H.H. Kramer, Jan M. Prins, P. H. Th. J. Slee, Karin Kaasjager, Andy I. M. Hoepelman	2006	129
11	Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial Diabetologia ·Mark M. Smits, Lennart Tonneijck, Marcel H.A. Muskiet, Mark H.H. Kramer, Petra J. W. Pouwels, Indra C. Pieters-van den Bos, Trynke Hoekstra, Michaëla Diamant, Daniël H. van Raalte, Djuna L. Cahen	2016	118
12	Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals European Journal of Endocrinology ·Renate T. de Jongh, Paul Lips, Natasja M. van Schoor, Kelly J. Rijs, D.J.H. Deeg, Hannie C. Comijs, Mark H.H. Kramer, Jan P. Vandenbroucke, Olaf M. Dekkers	2011	112
13	Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial Diabetologia ·Lennart Tonneijck, Mark M. Smits, Marcel H.A. Muskiet, Trynke Hoekstra, Mark H.H. Kramer, A.H. Jan Danser, Michaëla Diamant, Jaap A. Joles, Daniël H. van Raalte	2016	106
14	The Natural Course of Hemodynamically Stable Pulmonary Embolism CHEST Journal ·Mathilde Nijkeuter, Maaike Söhne, Lidwine W. Tick, Pieter W. Kamphuisen, Mark H.H. Kramer, L. Laterveer, Anja A. van Houten, Marieke J.H.A. Kruip, Frank W.G. Leebeek, Harry R. Büller, Menno V. Huisman	2007	103
15	Women with silicone breast implants and unexplained systemic symptoms: a descriptive cohort study. PubMed ·Maria C. Maijers, Christel J.M. de Blok, Frank B. Niessen, Astrid A.M. van der Veldt, Marco J.P.F. Ritt, Henri A. H. Winters, Mark H.H. Kramer, Prabath W.B. Nanayakkara	2013	103
16	Gene Variants in the Novel Type 2 Diabetes Loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B Affect Different Aspects of Pancreatic β-Cell Function Diabetes ·Annemarie M. Simonis-Bik, Giel Nijpels, Timon W. van Haeften, Jeanine J. Houwing‐Duistermaat, Dorret I. Boomsma, Erwin Reiling, Els C. van Hove, Michaëla Diamant, Mark H.H. Kramer, Robert J. Heine, J. A. Maassen, P. Eline Slagboom, Gonneke Willemsen, Joost Dekker, Elisabeth M. W. Eekhoff, Eco J. C. de Geus, Leen M. ‘t Hart	2009	102
17	Acute renal haemodynamic effects of glucagon‐like peptide‐1 receptor agonist exenatide in healthy overweight men Diabetes Obesity and Metabolism ·Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H.H. Kramer, M. Diamant, Jaap A. Joles, Daniël H. van Raalte	2015	86
18	Arterial Thrombosis and the Role of Thrombophilia Seminars in Thrombosis and Hemostasis ·S. Matthijs Boekholdt, Mark H.H. Kramer	2007	84
19	Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial Diabetes Care ·Lennart Tonneijck, Mark M. Smits, Marcel H.A. Muskiet, Trynke Hoekstra, Mark H.H. Kramer, A.H. Jan Danser, Piet M. ter Wee, Michaëla Diamant, Jaap A. Joles, Daniël H. van Raalte	2016	82
20	Effect of moderate-dose vitamin D supplementation on insulin sensitivity in vitamin D–deficient non-Western immigrants in the Netherlands: a randomized placebo-controlled trial American Journal of Clinical Nutrition ·Mirjam M Oosterwerff, Elisabeth M. W. Eekhoff, Natasja M. van Schoor, A. J. P. Boeke, P. G. C. L. Nanayakkara, Rosa Meijnen, Dirk L. Knol, Mark H.H. Kramer, Paul Lips	2014	73

About Mark H.H. Kramer

Mark H.H. Kramer is a scholar working on Family Practice, Internal Medicine, Endocrinology, Diabetes and Metabolism, Applied Microbiology and Biotechnology and Emergency Medicine, having authored 154 papers that have together received 5.8k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (42 papers), Diabetes Management and Research (21 papers), Pancreatic function and diabetes (17 papers), Emergency and Acute Care Studies (16 papers), Venous Thromboembolism Diagnosis and Management (13 papers), Diabetes and associated disorders (10 papers), Healthcare cost, quality, practices (10 papers) and Healthcare Policy and Management (8 papers). The work is most often cited by research in Internal Medicine (598 citations), Endocrinology, Diabetes and Metabolism (2.1k citations), Applied Microbiology and Biotechnology (166 citations), Nephrology (371 citations) and Family Practice (114 citations). Mark H.H. Kramer has collaborated with scholars based in Netherlands, United States and Vietnam. Frequent co-authors include Daniël H. van Raalte, Mark M. Smits, Marcel H.A. Muskiet, Lennart Tonneijck, Michaëla Diamant, Prabath W.B. Nanayakkara, Jaap A. Joles, Max Nieuwdorp, Trynke Hoekstra and Erik H. Serné. Their work appears in journals such as Diabetes Obesity and Metabolism, European Journal of Internal Medicine, European Journal of Endocrinology, Diabetes Care and Journal of Antimicrobial Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact